for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

UPDATE 1-MiddleBrook Pharmaceuticals files for bankruptcy

* Sees de-listing of stock from Nasdaq

* Says to ensure availability of its Moxatag drug

April 30 (Reuters) - MiddleBrook Pharmaceuticals Inc MBRK.O, which develops and makes anti-infective products, said it filed for Chapter 11 bankruptcy protection.

In court papers, MiddleBrook said it had assets of $42.2 million and debt of $29.1 million as of Dec. 31, 2009. The company said it expects to continue to manage and operate its business and assets during the bankruptcy period, and will promote its antibiotic Moxatag.

Last month, the company said its auditors had expressed doubts on the company’s ability to continue as a going concern, and its Chief Executive resigned as part of its plans to reduce staff. [ID:nSGE62B0I3]

The company said it expects de-listing of its stock from Nasdaq.

Shares of the company closed at 30 cents Friday on Nasdaq.

The case is In re: MiddleBrook Pharmaceuticals, U.S. Bankruptcy Court, District of Delaware, No. 10-11485. (Reporting by Shailesh Kuber in Bangalore; Editing by Aradhana Aravindan)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up